Journal Wrap | ACACIA-HCM, CARDIO-TTRansform
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.
ACACIA-HCM: Aficamten Benefits Symptomatic Nonobstructive HCM
Aficamten significantly improved exercise capacity and self-reported health status compared with placebo in patients with symptomatic nonobstructive HCM at 36 weeks, according to ACACIA-HCM, presented at ESC Congress 2026 and simultaneously published in NEJM.
CARDIO-TTRansform: Eplontersen Misses Primary Endpoint
Eplontersen, a once-monthly transthyretin gene silencer, did not significantly reduce cardiovascular mortality or recurrent cardiovascular events vs. placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to results from the CARDIO-TTRansform trial presented at ESC Congress 2026 and simultaneously published in NEJM.
Clinical Topics: Heart Failure and Cardiomyopathies
Keywords: Cardiology Magazine, ACC Publications, CM-Oct-2026, ESC Congress, ESC26, Cardiomyopathies, Hypertrophic Cardiomyopathy, Amyloidosis
